Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets

Non-alcoholic fatty liver disease (NAFLD) and atherosclerosis (ATS) are worldwide known diseases with increased incidence and prevalence. These two are driven and are interconnected by multiple oxidative and metabolic functions such as lipotoxicity. A gamut of evidence suggests that sphingolipids (S...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Daniela Maria Tanase, Evelina Maria Gosav, Daniela Petrov, Alina Ecaterina Jucan, Cristina Mihaela Lacatusu, Mariana Floria, Claudia Cristina Tarniceriu, Claudia Florida Costea, Manuela Ciocoiu, Ciprian Rezus
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	non-alcoholic fatty liver disease NAFLD ceramide sphingolipids SL atherosclerosis Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/3a41075c8eef45898629d8de4bad3f0c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3a41075c8eef45898629d8de4bad3f0c
record_format	dspace
spelling	oai:doaj.org-article:3a41075c8eef45898629d8de4bad3f0c2021-11-25T17:21:13ZInvolvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets10.3390/diagnostics111120532075-4418https://doaj.org/article/3a41075c8eef45898629d8de4bad3f0c2021-11-01T00:00:00Zhttps://www.mdpi.com/2075-4418/11/11/2053https://doaj.org/toc/2075-4418Non-alcoholic fatty liver disease (NAFLD) and atherosclerosis (ATS) are worldwide known diseases with increased incidence and prevalence. These two are driven and are interconnected by multiple oxidative and metabolic functions such as lipotoxicity. A gamut of evidence suggests that sphingolipids (SL), such as ceramides, account for much of the tissue damage. Although in humans they are proving to be accurate biomarkers of adverse cardiovascular disease outcomes and NAFLD progression, in rodents, pharmacological inhibition or depletion of enzymes driving de novo ceramide synthesis prevents the development of metabolic driven diseases such as diabetes, ATS, and hepatic steatosis. In this narrative review, we discuss the pathways which generate the ceramide synthesis, the potential use of circulating ceramides as novel biomarkers in the development and progression of ATS and related diseases, and their potential use as therapeutic targets in NAFDL-ATS development which can further provide new clues in this field.Daniela Maria TanaseEvelina Maria GosavDaniela PetrovAlina Ecaterina JucanCristina Mihaela LacatusuMariana FloriaClaudia Cristina TarniceriuClaudia Florida CosteaManuela CiocoiuCiprian RezusMDPI AGarticlenon-alcoholic fatty liver diseaseNAFLDceramidesphingolipidsSLatherosclerosisMedicine (General)R5-920ENDiagnostics, Vol 11, Iss 2053, p 2053 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	non-alcoholic fatty liver disease NAFLD ceramide sphingolipids SL atherosclerosis Medicine (General) R5-920
spellingShingle	non-alcoholic fatty liver disease NAFLD ceramide sphingolipids SL atherosclerosis Medicine (General) R5-920 Daniela Maria Tanase Evelina Maria Gosav Daniela Petrov Alina Ecaterina Jucan Cristina Mihaela Lacatusu Mariana Floria Claudia Cristina Tarniceriu Claudia Florida Costea Manuela Ciocoiu Ciprian Rezus Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets
description	Non-alcoholic fatty liver disease (NAFLD) and atherosclerosis (ATS) are worldwide known diseases with increased incidence and prevalence. These two are driven and are interconnected by multiple oxidative and metabolic functions such as lipotoxicity. A gamut of evidence suggests that sphingolipids (SL), such as ceramides, account for much of the tissue damage. Although in humans they are proving to be accurate biomarkers of adverse cardiovascular disease outcomes and NAFLD progression, in rodents, pharmacological inhibition or depletion of enzymes driving de novo ceramide synthesis prevents the development of metabolic driven diseases such as diabetes, ATS, and hepatic steatosis. In this narrative review, we discuss the pathways which generate the ceramide synthesis, the potential use of circulating ceramides as novel biomarkers in the development and progression of ATS and related diseases, and their potential use as therapeutic targets in NAFDL-ATS development which can further provide new clues in this field.
format	article
author	Daniela Maria Tanase Evelina Maria Gosav Daniela Petrov Alina Ecaterina Jucan Cristina Mihaela Lacatusu Mariana Floria Claudia Cristina Tarniceriu Claudia Florida Costea Manuela Ciocoiu Ciprian Rezus
author_facet	Daniela Maria Tanase Evelina Maria Gosav Daniela Petrov Alina Ecaterina Jucan Cristina Mihaela Lacatusu Mariana Floria Claudia Cristina Tarniceriu Claudia Florida Costea Manuela Ciocoiu Ciprian Rezus
author_sort	Daniela Maria Tanase
title	Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets
title_short	Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets
title_full	Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets
title_fullStr	Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets
title_full_unstemmed	Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets
title_sort	involvement of ceramides in non-alcoholic fatty liver disease (nafld) atherosclerosis (ats) development: mechanisms and therapeutic targets
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/3a41075c8eef45898629d8de4bad3f0c
work_keys_str_mv	AT danielamariatanase involvementofceramidesinnonalcoholicfattyliverdiseasenafldatherosclerosisatsdevelopmentmechanismsandtherapeutictargets AT evelinamariagosav involvementofceramidesinnonalcoholicfattyliverdiseasenafldatherosclerosisatsdevelopmentmechanismsandtherapeutictargets AT danielapetrov involvementofceramidesinnonalcoholicfattyliverdiseasenafldatherosclerosisatsdevelopmentmechanismsandtherapeutictargets AT alinaecaterinajucan involvementofceramidesinnonalcoholicfattyliverdiseasenafldatherosclerosisatsdevelopmentmechanismsandtherapeutictargets AT cristinamihaelalacatusu involvementofceramidesinnonalcoholicfattyliverdiseasenafldatherosclerosisatsdevelopmentmechanismsandtherapeutictargets AT marianafloria involvementofceramidesinnonalcoholicfattyliverdiseasenafldatherosclerosisatsdevelopmentmechanismsandtherapeutictargets AT claudiacristinatarniceriu involvementofceramidesinnonalcoholicfattyliverdiseasenafldatherosclerosisatsdevelopmentmechanismsandtherapeutictargets AT claudiafloridacostea involvementofceramidesinnonalcoholicfattyliverdiseasenafldatherosclerosisatsdevelopmentmechanismsandtherapeutictargets AT manuelaciocoiu involvementofceramidesinnonalcoholicfattyliverdiseasenafldatherosclerosisatsdevelopmentmechanismsandtherapeutictargets AT ciprianrezus involvementofceramidesinnonalcoholicfattyliverdiseasenafldatherosclerosisatsdevelopmentmechanismsandtherapeutictargets
_version_	1718412463863496704

Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets

Ejemplares similares